Guidelines of 19 March 2015 on the formalised risk assessment for ascertaining the appropriate good manufacturing practice for excipients of medicinal products
Was is the current impact on excipient manufacturers and users on these guidelines?
Was is the current impact on excipient manufacturers and users on these guidelines?